Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Tuesday that its partner Eisai Co Ltd's (TYO:4523) Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosing has been accepted by the US Food and Drug Administration (FDA).
Leqembi is indicated for the treatment of Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI) or mild dementia stage of disease. It is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option. The Prescription Drug User Fee Act (PDUFA) action date has been set to 31 August 2025.
The BLA is based on data from the Clarity AD (Study 301) open-label extension and modelling of observed data. The SC-AI 360 mg weekly maintenance regimen will allow patients who have completed the biweekly intravenous (IV) initiation phase, exact period under discussion with the FDA, to receive weekly doses that are expected to maintain the clinical and biomarker benefits.
Leqembi is already approved in the United States, Japan, China, Great Britain and other markets. In November 2024 the treatment received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval.
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval
Biohaven secures FDA priority review for troriluzole in spinocerebellar ataxia
Owens & Minor launches ByramConnect digital health platform for diabetes management
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
bioMérieux secures US FDA clearance for new gastrointestinal diagnostic panel
EssilorLuxottica expands med-tech portfolio with Cellview acquisition
Axsome Therapeutics settles patent litigation with Teva over AUVELITY
Hemab Therapeutics reveals interim data from ongoing HMB-001 phase two study
AbbVie's EMBLAVEO receives US FDA approval for complicated intra-abdominal infections
Eton Pharmaceuticals secures US patent for ET-600, protecting formulation through 2044
Lilly's Omvoh shows sustained efficacy in Crohn's disease after two years
Bio-Thera Solutions secures EMA acceptance for BAT2506 biosimilar application
BioArctic reports strong royalty growth from Leqembi sales in Q4 2024